Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jodie Moore

Registered Nurse Sherman, TX Nurse Practitioner

NPI 1730497355 CMS profile 10619693

321 N Highland Ave, Ste 200, Sherman, TX 75092

Open in the dashboard

General payments

$4,753

267 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jodie Moore of Sherman, TX is reported in the CMS Open Payments database as having received $4,753 across 267 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Registered Nurse profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $58 2
2024 General $1,023 55
2023 General $1,506 86
2022 General $1,266 73
2021 General $899 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jodie Moore
  • Registered Nurse median
  • Middle half of Registered Nurse
  • National median

In program year 2025, general payments to Jodie Moore were reported at $58. Among 1,661 Registered Nurse profiles paid that year, the median was $74 and the middle half received between $27 and $193.

Show as a table
Year Jodie Moore Registered Nurse median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $899 $53 $20–$148 $132
2022 $1,266 $53 $21–$146 $149
2023 $1,506 $84 $26–$196 $160
2024 $1,023 $80 $26–$187 $164
2025 $58 $74 $27–$193 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,009 65 payments
  2. Pfizer Inc. $368 28 payments
  3. Celgene Corporation $288 16 payments
  4. Biogen, Inc. $287 13 payments
  5. UCB, Inc. $210 11 payments
  6. ACADIA Pharmaceuticals Inc $182 9 payments
  7. Teva Pharmaceuticals USA, Inc. $169 9 payments
  8. Amgen Inc. $149 7 payments
  9. Eisai Inc. $135 6 payments
  10. Alexion Pharmaceuticals, Inc. $118 6 payments
  11. Other $1,840 97 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,753 267 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $384 26 payments
  2. NURTEC ODT $368 28 payments
  3. ZEPOSIA $288 16 payments
  4. UBRELVY $263 19 payments
  5. BOTOX Botox Therapeutic $206 12 payments
  6. BOTOX Hyperhydrosis $178 11 payments
  7. DUOPA $169 10 payments
  8. VUMERITY $135 6 payments
  9. Briviact $131 8 payments
  10. NUPLAZID $124 6 payments
  11. Other $2,968 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

267 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record